Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD – Free Report) from a buy rating to a strong-buy rating in a research note published on Sunday morning,Wall Street Zen reports.

A number of other analysts have also commented on the stock. Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Jefferies Financial Group upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Friday, September 25th. Finally, Zacks Research cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Ironwood Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $6.23.

Check Out Our Latest Stock Analysis on Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $4.83 on Friday. Ironwood Pharmaceuticals has a 12 month low of $2.95 and a 12 month high of $5.78. The stock has a market capitalization of $799.61 million, a price-to-earnings ratio of 5.37 and a beta of 0.25. The firm has a fifty day simple moving average of $3.97 and a two-hundred day simple moving average of $3.96.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.04. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. The firm had revenue of $133.04 million for the quarter, compared to analyst estimates of $119.99 million. Equities analysts predict that Ironwood Pharmaceuticals will post 1.10 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Principal Financial Group Inc. bought a new stake in Ironwood Pharmaceuticals in the 1st quarter worth about $40,000. Bull Harbor Capital LLC bought a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $48,000. Ascent Group LLC bought a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter worth approximately $58,000. Chicago Partners Investment Group LLC bought a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $65,000. Finally, Private Wealth Asset Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 160.5% in the 3rd quarter. Private Wealth Asset Management LLC now owns 15,632 shares of the biotechnology company’s stock worth $69,000 after buying an additional 9,632 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

(Get Free Report)

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.

Recommended Stories

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.